Investment28 Aug 2025, 01:22 pm
Sai Life Sciences Expands Capacity to 700 KL with Completion of Phase II of Production Block 11 at Bidar Facility
AI Summary
Sai Life Sciences Limited, a Contract Research, Development, and Manufacturing Organization (CRDMO), has completed the second phase of its new Production Block (PB-11) at the company’s flagship API manufacturing facility in Bidar, India. This expansion has taken the company’s total installed reactor capacity at the Bidar facility to ~700 KL.
Key Highlights
- Sai Life Sciences has expanded its capacity to 700 KL at its Bidar facility.
- The second phase of Production Block 11 (PB-11) has a capacity of ~91 KL.
- The Bidar site is the company’s flagship manufacturing site, specializing in the production of APIs and advanced intermediates for highly regulated markets such as the US, EU, and Japan.
- The facility has been successfully inspected and approved by leading global regulatory agencies including the USFDA, PMDA (Japan), and CDSCO (India).
- Sai Life Sciences has served over 300 global innovator pharma and biotech companies in the past 26 years.